Stock Scorecard
Stock Summary for Applied Therapeutics Inc (APLT) - $0.21 as of 12/3/2025 5:25:09 PM EST
Total Score
9 out of 30
Safety Score
20 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for APLT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for APLT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for APLT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for APLT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for APLT (20 out of 100)
| Stock Price Rating (Max of 10) | 1 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for APLT
Financial Details for APLT
Company Overview |
|
|---|---|
| Ticker | APLT |
| Company Name | Applied Therapeutics Inc |
| Country | USA |
| Description | Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, dedicated to developing innovative therapies for unmet medical needs in areas such as cardiovascular diseases, galactosemia, and diabetes-related complications. The company's robust pipeline focuses on novel compounds designed to address significant health challenges, showcasing a commitment to cutting-edge research and patient-centric solutions. As it advances through clinical trials, Applied Therapeutics is poised to become a transformative force in the treatment landscape, aiming to significantly enhance patient outcomes in its targeted therapeutic areas. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 0.21 |
| Price 4 Years Ago | 8.95 |
| Last Day Price Updated | 12/3/2025 5:25:09 PM EST |
| Last Day Volume | 5,609,828 |
| Average Daily Volume | 18,085,966 |
| 52-Week High | 1.50 |
| 52-Week Low | 0.21 |
| Last Price to 52 Week Low | 0.00% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 43.11 |
| Sector PE | 88.06 |
| 5-Year Average PE | 1.31 |
| Free Cash Flow Ratio | 2.63 |
| Industry Free Cash Flow Ratio | 13.81 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 0.96 |
| Total Cash Per Share | 0.08 |
| Book Value Per Share Most Recent Quarter | 0.00 |
| Price to Book Ratio | 7.72 |
| Industry Price to Book Ratio | 33.69 |
| Sector Price to Book Ratio | 33.12 |
| Price to Sales Ratio Twelve Trailing Months | 30.72 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.75 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.97 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 144,301,000 |
| Market Capitalization | 30,303,210 |
| Institutional Ownership | 69.61% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 11.81% |
| Reported EPS 12 Trailing Months | -0.10 |
| Reported EPS Past Year | 0.05 |
| Reported EPS Prior Year | -0.80 |
| Net Income Twelve Trailing Months | -18,138,000 |
| Net Income Past Year | -105,624,000 |
| Net Income Prior Year | -119,763,000 |
| Quarterly Revenue Growth YOY | 720.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -1,797.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 11,945,000 |
| Total Cash Past Year | 79,398,000 |
| Total Cash Prior Year | 49,898,000 |
| Net Cash Position Most Recent Quarter | 11,945,000 |
| Net Cash Position Past Year | 78,934,000 |
| Long Term Debt Past Year | 464,000 |
| Long Term Debt Prior Year | 464,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.99 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | 57,006,000 |
| Total Stockholder Equity Prior Year | -17,146,000 |
| Total Stockholder Equity Most Recent Quarter | -561,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -86,847,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.60 |
| Free Cash Flow Past Year | -84,305,000 |
| Free Cash Flow Prior Year | -55,173,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.19 |
| MACD Signal | -0.18 |
| 20-Day Bollinger Lower Band | -0.10 |
| 20-Day Bollinger Middle Band | 0.65 |
| 20-Day Bollinger Upper Band | 1.39 |
| Beta | 1.93 |
| RSI | 28.81 |
| 50-Day SMA | 2.56 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 2.25 |
System |
|
| Modified | 12/3/2025 5:25:10 PM EST |